Neopharm to sell Orexo's Abstral in Israel

Sweden's Orexo has signed an exclusive distribution agreement that grants Neopharm rights to market and sell Abstral (fentanyl), its  product for treatment of breakthrough cancer pain, for that market.  Orexo will supply Neopharm with the drug in Israel and receive  significant margin on sales. The agreement also includes milestone  payments, but further financial terms were not disclosed. Neopharm will  also be responsible for managing the regulatory approval process in  Israel.

Torbjorn Bjerke, chief executive of Orexo, said: "this agreement with  Neopharm will enable sales of Abstral on additional geographic markets  and is another step in developing Orexo into a profitable pharmaceutical  company. Neopharm has one of the most experienced marketing and sales  organizations in Israel, with pain and oncology expertise, which makes  them a perfect partner for Orexo in Israel."